Dose escalation for stereotactic arrhythmia radioablation of recurrent ventricular tachyarrhythmia - a phase II clinical trial
Boldizsar Kovacs(University of Bern), Nicolaus Andratschke(University Hospital of Zurich), Alexandros Papachristofilou(University Hospital of Basel), Frank Ruschitzka(University Hospital of Zurich), Lorraine Sazgary(University of Zurich), Matthias Gückenberger(University of Zurich), Robert Manka(University of Zurich), Ardan M. Saguner(Zurich Heart House), Krzysztof S. Gołba(Mount Sinai Hospital), Stefanie Ehrbar(University of Zurich), Fırat Duru(University of Zurich), Maiwand Ahmadsei(University Hospital of Zurich), Christian Sticherling(Sichuan University), Hatem Alkadhi(University of Zurich), Sławomir Blamek(The Maria Sklodowska-Curie National Research Institute of Oncology), Michael Mayinger(University Hospital of Zurich), Debra Fesslmeier(University Hospital of Zurich)
Cited by 8
Related Papers
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2023|2.2k
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Advanced Heart Failure: A Position Statement of the Heart Failure Association of the European Society of Cardiology
|European Journal of Heart Failure|2018|846
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
Type 2 Diabetes Mellitus and Heart Failure: A Position Statement from the Heart Failure Association of the European Society of Cardiology
|European Journal of Heart Failure|2018|714